Placenta, Journal Year: 2024, Volume and Issue: 160, P. 1 - 10
Published: Dec. 28, 2024
Language: Английский
Journal of Molecular Neuroscience, Journal Year: 2025, Volume and Issue: 75(1)
Published: March 13, 2025
Abstract Neurodegenerative disorders, including Alzheimer’s disease (AD), Parkinson’s (PD), multiple sclerosis (MS), and amyotrophic lateral (ALS), are characterized by the progressive gradual degeneration of neurons. The prevalence rates these disorders rise significantly with age. As life spans continue to increase in many countries, number cases is expected grow foreseeable future. Early precise diagnosis, along appropriate surveillance, continues pose a challenge. high heterogeneity neurodegenerative diseases calls for more accurate definitive biomarkers improve clinical therapy. Cell-free DNA (cfDNA), fragmented released into bodily fluids via apoptosis, necrosis, or active secretion, has emerged as promising non-invasive diagnostic tool various diseases. cfDNA can serve an indicator ongoing cellular damage mortality, neuronal loss, may provide valuable insights processes, progression, therapeutic responses. This review will first cover key aspects then examine recent advances its potential use biomarker disorders.
Language: Английский
Citations
1
Diagnostics, Journal Year: 2024, Volume and Issue: 14(10), P. 1045 - 1045
Published: May 17, 2024
Circulating cfRNA in plasma has emerged as a fascinating area of research with potential applications disease diagnosis, monitoring, and personalized medicine. RNA sequencing technology allows for the non-invasive collection important information about expression target genes, eliminating need biopsies. This comprehensive review aims to provide detailed overview current knowledge advancements study cfRNA, focusing on its diverse landscape biological functions, detection methods, diagnostic prognostic various diseases, challenges, future perspectives.
Language: Английский
Citations
5
Practical Laboratory Medicine, Journal Year: 2024, Volume and Issue: unknown, P. e00446 - e00446
Published: Dec. 1, 2024
Liquid biopsy is an innovative, minimally invasive diagnostic tool revolutionizing cancer management by enabling the detection and analysis of cancer-related biomarkers from bodily fluids such as blood, urine, or cerebrospinal fluid. Unlike traditional tissue biopsies, which require procedures, liquid offers a more accessible repeatable method for tracking progression, detecting early-stage cancers, monitoring therapeutic responses. The technology primarily focuses on analyzing circulating tumor cells (CTCs), DNA (ctDNA), other cancer-derived genetic materials. These provide critical information heterogeneity, mutation profiles, potential drug resistance. In clinical practice, has demonstrated its utility in identifying actionable mutations, guiding personalized treatment strategies, assessing minimal residual disease (MRD). While holds immense promise, challenges related to sensitivity, specificity, standardization remain. Efforts optimize pre-analytical analytical processes, along with establishment robust regulatory frameworks, are crucial widespread adoption. This abstract highlights transformative diagnosis, prognosis, monitoring, emphasizing role advancing oncology. Further research, trials, harmonization will be vital realizing full precision care.
Language: Английский
Citations
4
Trends in biotechnology, Journal Year: 2025, Volume and Issue: unknown
Published: Jan. 1, 2025
Language: Английский
Citations
0
Journal of Translational Medicine, Journal Year: 2025, Volume and Issue: 23(1)
Published: Feb. 3, 2025
Transplant rejection remains a significant barrier to the long-term success of organ transplantation. Biopsy, although considered gold standard, is invasive, costly, and unsuitable for routine monitoring. Traditional biomarkers, such as creatinine troponin, offer limited predictive value owing their low specificity, conventional imaging techniques often fail detect early damage, increasing risk undiagnosed episodes. Considering these limitations, emerging noninvasive biomarkers molecular hold promise accurate detection transplant rejection, enabling personalized management strategies. This review highlights that predict, diagnose, assess prognosis by reflecting graft injury, inflammation, immune responses. For example, donor-derived cell-free DNA (dd-cfDNA) highly sensitive in detecting whereas gene expression profiling effectively excludes moderate-to-severe acute (AR). Additionally, microRNA (miRNA) enhances diagnostic specificity precise AR detection. Advanced further augment monitoring rejection. Fluorescence provides high spatiotemporal resolution grading, ultrasound offers real-time portable monitoring, magnetic resonance delivers tissue contrast anatomical assessments. Nuclear modalities single photon emission computed tomography positron tomography, enable dynamic visualization responses within transplanted organs. Notably, dd-cfDNA nuclear medicine have already been integrated into clinical practice, thereby demonstrating translational potential techniques. Unlike previous reviews, this work uniquely synthesizes advancements both imaging, emphasizing complementary strengths. Biomarkers deliver molecular-level insights, spatial temporal resolution. Together, they create synergistic framework comprehensive By bridging domains, underscores individual contributions collective enhance accuracy, improve patient outcomes, guide future research applications medicine.
Language: Английский
Citations
0
International Journal of Molecular Sciences, Journal Year: 2025, Volume and Issue: 26(4), P. 1530 - 1530
Published: Feb. 12, 2025
Rapid identification of acute ischemic stroke (AIS) is challenging in both pre-hospital and hospital settings. We aimed to identify the most promising cell-free nucleic acids (cfNAs) as diagnostic biomarkers for IS within 72 h from symptom onset. searched PubMed, Web Science, EMBASE, Cochrane Library published articles that evaluated blood cfNAs early diagnosis AIS until 10 May 2023. The performances individual were pooled by random-effects meta-analysis based on fold change biomarkers' level between non-AIS patients. Of 2955 records, 66 reporting 143 different met inclusion criteria. median sample size was 110, 21.4% studies performed validation. Among selected high-quality studies, miR-106b-5p, miR-124, miR-155, lncRNA H19, cfDNA showed good performance. Data four involving 355 patients 97 controls meta-analysis, which a significant (pooled ratio 1.48, 95% confidence interval 1.23-1.79, p < 0.001). This review highlights cfDNA, H19 are diagnosis, further research needed verification.
Language: Английский
Citations
0
medRxiv (Cold Spring Harbor Laboratory), Journal Year: 2025, Volume and Issue: unknown
Published: Feb. 21, 2025
Summary The 2024 Nobel Prize in Physiology or Medicine was awarded to the pioneers who reported that microRNAs (miRNAs) regulate and direct switch between physiological pathological pathways via their over- under-expression. discovery has not yielded any health benefit primarily due raw data with no clear distinction healthy diseased blood samples. MiRNAs exist at femtomolar level biological fluids, typically quantified using amplification-based techniques. Experimental nanopores have illustrated potential for trace analysis including amplification-free miRNA quantification. We repurposed MinION, only commercially available nanopore-array device, developed unique probes protocols quantify urine. Our report revealed (i) copies are proportional total RNA isolated from biospecimen, (ii) several known cancer biomarkers were 1.8-fold overexpressed samples breast, prostate pancreatic patients compared healthy. In contrast literature reports sample variability undetectable after normalization same content. Here earlier confirmed, conclusions extended ovarian, lung, colorectal cancer. of ready-to-use MinION/Yenos platform multiple early detection (MCED) urine is discussed.
Language: Английский
Citations
0
Biomedical Journal, Journal Year: 2025, Volume and Issue: unknown, P. 100839 - 100839
Published: Feb. 1, 2025
Language: Английский
Citations
0
RNA Biology, Journal Year: 2025, Volume and Issue: unknown
Published: March 20, 2025
Circulating cell-free RNA (cfRNA) has emerged as a promising analyte for disease detection. However, the comprehensive profiling of diverse cfRNA types remains under-characterized. Here, we applied new wide-spectrum sequencing method and simultaneously captured rRNA, tRNA, mRNA, miRNA, lncRNA, all mitochondrial RNA. The compositions, size distributions, highly abundant genes were analyzed each type cfRNA. We depicted cell origin profiles 66 generally healthy individuals found that BMI showed significant impact on kidney-derived proportion. Three with some liver problems identified because relatively high levels hepatocyte-specific abundance different types, including miRNA significantly correlated function test results. individual variances enriched in pathways associated common diseases such diseases, virus infections, cancers, metabolic diseases. This study provided displayed potential biomarker health monitoring.
Language: Английский
Citations
0
Med, Journal Year: 2025, Volume and Issue: unknown, P. 100646 - 100646
Published: April 1, 2025
Urinary cell-free DNA (ucfDNA) is a valuable resource for truly non-invasive liquid biopsy. UcfDNA comprises transrenal ucfDNA passing from the bloodstream through glomeruli and locally shed urinary-tract ucfDNA. Understanding their differences in characteristics may enable new diagnostic applications. We analyzed 136 samples healthy controls, pregnant women, patients with chronic kidney diseases (CKDs), bladder cancer using massively parallel sequencing. Fragmentomic including fragment sizes 5' end motifs were deduced. The relationship between chromatin accessibility was examined by overlapping open regions (OCRs, lacking histones) heterochromatin (HCRs, tightly packed histones). Compared ucfDNA, shorter enriched C-ends. over-represented OCRs but depleted HCRs, indicating an interplay glomerular filtration barrier effective cfDNA size. In proteinuria (preeclampsia CKDs), amount of HCRs increased, suggesting elevated permeability histone-bound plasma molecules. oncology, use hypomethylation signals enhanced detection, area under receiver operating characteristic curve 0.93. Chromatin states impact clearance DNA, likely size restriction barrier. This realization has enabled rational development novel approaches detecting or monitoring renal dysfunction urological cancers. Innovation Technology Commission Hong Kong SAR Government (InnoHK initiative) Li Ka Shing Foundation supported this study.
Language: Английский
Citations
0